FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1

Migration, Crosslink

📖

FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-flvcr1

📖 Wiki Page

gene2444 wordssynced 2026-04-02

FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>FLVCR1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Feline Leukemia Virus Subgroup C Receptor 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q32.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>28982</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>609033</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000117498</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9Y5Z0</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Major Facilitator Superfamily (MFS) transporter</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Hereditary Sensory Autonomic Neuropathy (HSAN1)</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>AKT phosphorylates FLVCR1, enhancing its activity; FLVCR1 supports AKT signaling by maintaining mitochondrial function</td>
</tr>
<tr>
<td class="label">Nrf2/ARE</td>
<td>Heme accumulation activates Nrf2; FLVCR1 prevents excessive activation that could disrupt cellular homeostasis</td>
</tr

...

FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>FLVCR1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Feline Leukemia Virus Subgroup C Receptor 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q32.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>28982</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>609033</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000117498</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9Y5Z0</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Major Facilitator Superfamily (MFS) transporter</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Hereditary Sensory Autonomic Neuropathy (HSAN1)</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>AKT phosphorylates FLVCR1, enhancing its activity; FLVCR1 supports AKT signaling by maintaining mitochondrial function</td>
</tr>
<tr>
<td class="label">Nrf2/ARE</td>
<td>Heme accumulation activates Nrf2; FLVCR1 prevents excessive activation that could disrupt cellular homeostasis</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>mTORC1 activity is sensitive to cellular heme levels; FLVCR1-mediated heme export supports proper mTOR signaling</td>
</tr>
<tr>
<td class="label">JAK/STAT</td>
<td>Cytokine signaling affects FLVCR1 expression; FLVCR1, in turn, modulates cytokine-induced oxidative stress</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Motor cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>High</td>
</tr>
<tr>
<td class="label">Peripheral nerves</td>
<td>High</td>
</tr>
</table>

FLVCR1 (Feline Leukemia Virus Subgroup C Receptor 1) encodes a member of the Major Facilitator Superfamily (MFS) of transporters that functions as a cellular heme exporter. Originally identified as the receptor for feline leukemia virus subgroup C, this protein has evolved to play essential roles in heme metabolism, iron homeostasis, and cellular protection against heme-induced oxidative stress. FLVCR1 is ubiquitously expressed but shows particularly high expression in the [substantia nigra](/brain-regions/substantia-nigra), [hippocampus](/brain-regions/hippocampus), and motor [cortex](/brain-regions/cortex)—brain regions prominently affected in neurodegenerative diseases.

The critical importance of FLVCR1 in neuronal health is underscored by its association with several neurodegenerative conditions, including [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis (ALS)/diseases/amyotrophic-lateral-sclerosis), and hereditary sensory and autonomic neuropathy type I (HSAN1). The transporter protects neurons from the toxic effects of intracellular heme accumulation while simultaneously supporting essential heme-dependent processes including mitochondrial respiration, neurotransmitter synthesis, and antioxidant defense. [@flvcr1_disease_2023]

Overview

Function

FLVCR1 functions as a proton-coupled heme antiporter, utilizing the transmembrane proton gradient to export intracellular heme against its concentration gradient. The protein contains 12 transmembrane helices organized in the classic MFS transporter fold, with N- and C-termini facing the cytoplasm. The heme-binding site is located within the central cavity formed by the transmembrane helices, allowing for selective transport of heme while excluding other porphyrins and protoporphyrins. [@flvcr1_structure_2020]

Heme Export Activity

The primary function of FLVCR1 is the export of cellular heme, a critically important process for several reasons:

Heme detoxification: Free heme (non-hemoprotein-bound heme) is highly reactive and can generate reactive oxygen species (ROS) through Fenton chemistry. FLVCR1 prevents heme accumulation by exporting excess heme to extracellular acceptors or to peripheral tissues. [@flvcr1_oxidative_2015]

Iron recycling: Exported heme can be degraded by heme oxygenase to release iron for reutilization in erythropoiesis or storage in ferritin. This makes FLVCR1 a key component of systemic iron recycling. [@flvcr1_erythropoiesis_2017]

Cellular heme pool regulation: The concentration of intracellular free heme must be carefully balanced—sufficient for heme-dependent processes but below toxic thresholds. FLVCR1 provides dynamic regulation of this pool in response to cellular needs. [@flvcr1_mfs_2016]

Mitochondrial Function Support

FLVCR1 plays an essential role in mitochondrial function through its regulation of mitochondrial heme homeostasis:

Heme delivery to mitochondria: While FLVCR1 exports heme from cells, it also supports mitochondrial heme uptake by maintaining appropriate cytosolic heme concentrations
Cytochrome synthesis: Mitochondrial heme is required for the synthesis of cytochromes in the electron transport chain
Respiratory complex assembly: Proper heme trafficking supports assembly of Complexes I, II, III, and IV

Research has demonstrated that FLVCR1 deficiency leads to impaired mitochondrial respiration and reduced ATP production in neurons. [@flvcr1_mito_2014]

Neuroprotection Mechanisms

FLVCR1 provides neuroprotection through multiple interconnected mechanisms:

Oxidative stress mitigation: By preventing heme accumulation, FLVCR1 limits iron-catalyzed ROS generation

Neuroinflammation modulation: Heme export reduces microglial activation and pro-inflammatory cytokine production

Dopamine metabolism support: FLVCR1 influences dopamine synthesis by regulating intracellular heme availability for tyrosine hydroxylase

Autophagy regulation: Heme export supports proper autophagic flux, critical for清除 damaged proteins and organelles

The transporter is particularly important in [dopaminergic neurons](/cell-types/dopaminergic-neurons) of the substantia nigra, which are uniquely vulnerable to oxidative stress due to their dopamine metabolism. [@dopa_2013]

Molecular Mechanisms

Structure-Function Relationship

FLVCR1 adopts the canonical MFS transporter fold with 12 transmembrane α-helices arranged in two pseudo-symmetric bundles of six helices each. The transporter undergoes conformational changes between outward-facing and inward-facing states during the transport cycle. Key structural features include:

Transmembrane domain: 12 helices (TM1-TM12) forming the transport pore
Nucleotide-binding domain: Cytoplasmic loop between TM6 and TM7
Heme-binding motif: Conserved residues in TM4 and TM10 coordinate heme transport
Proton coupling residues: Acidic residues in TM2 and TM8 facilitate proton coupling

The transport mechanism involves a "rocker-switch" model where alternating access to the heme-binding site is achieved through rigid-body movements of the two helical bundles. [@flvcr1_structure_2020]

Signaling Pathways

FLVCR1 interacts with several key cellular signaling pathways:

Transcriptional Regulation

FLVCR1 expression is regulated at multiple levels:

Heme-dependent regulation: Heme itself can regulate FLVCR1 transcription through HRARE (heme-responsive autophagy regulatory element) sequences in the promoter
Hypoxia-inducible factor (HIF): FLVCR1 is a HIF target gene, induced under low oxygen conditions
Oxidative stress: Nrf2 activation increases FLVCR1 expression as part of the antioxidant response
Developmental regulation: FLVCR1 expression increases during neural development, coinciding with increased heme demand for myelination

Disease Associations

Parkinson's Disease

FLVCR1 is implicated in [Parkinson's disease](/diseases/parkinsons-disease) through several mechanisms:

Iron Dysregulation in the Substantia Nigra

The substantia nigra pars compacta (SNc) contains the highest iron concentration in the brain and is the primary site of neurodegeneration in PD. FLVCR1 expression is significantly reduced in the SNc of PD patients, leading to:

Heme accumulation: Impaired heme export causes intracellular heme buildup
Iron overload: Reduced heme export disrupts iron recycling, contributing to iron accumulation
Increased oxidative stress: Heme and iron accumulation catalyze ROS generation
Dopaminergic neuron vulnerability: Combined effects promote neuronal death

Studies have demonstrated that FLVCR1 protein levels are decreased by approximately 40% in the SNc of PD patients compared to age-matched controls. This reduction correlates with disease severity and is particularly pronounced in patients with the [LRRK2](/genes/lrrk2) G2019S mutation. [@flvcr1_pd_2022]

Interaction with PD Genes

FLVCR1 intersects with several established PD genetic risk factors:

[LRRK2](/genes/lrrk2): LRK2 kinase activity affects FLVCR1 phosphorylation and trafficking; G2019S mutation alters this interaction
[PARKIN](/genes/parkin): PINK1/Parkin mitophagy regulates FLVCR1 degradation; impaired mitophagy leads to FLVCR1 accumulation in dysfunctional mitochondria
[GBA](/genes/gba): Glucocerebrosidase deficiency affects heme metabolism; FLVCR1 expression is altered in GBA carriers
[SNCA](/genes/snca): Alpha-synuclein aggregation may sequester FLVCR1, impairing its function

Therapeutic Implications

Targeting FLVCR1 in PD represents a novel therapeutic approach:

Small molecule activators: Compounds that enhance FLVCR1 activity could improve heme export

Gene therapy: AAV-mediated FLVCR1 overexpression in the SNc

Iron chelation: Complementary to FLVCR1 enhancement by reducing iron burden

Combination approaches: FLVCR1 modulation with existing PD therapies

A biomarker study identified FLVCR1 levels in cerebrospinal fluid as a potential biomarker for iron dysregulation in PD, with reduced FLVCR1 correlating with disease severity. [@flvcr1_biomarker_2023]

Amyotrophic Lateral Sclerosis (ALS)

FLVCR1 mutations and expression changes are associated with [ALS/diseases/amyotrophic-lateral-sclerosis):

Motor Neuron Vulnerability

Motor neurons are particularly dependent on proper heme metabolism due to their high energy demands and reliance on mitochondrial function:

High metabolic demand: Motor neurons require substantial ATP production, demanding efficient mitochondrial respiration
Axonal length: Long axonal projections require extensive mitochondrial distribution
Calcium handling: Motor neurons rely on mitochondrial calcium buffering, affected by heme-dependent respiration

FLVCR1 expression is reduced in spinal motor neurons from ALS patients, and this reduction is more pronounced in sporadic ALS than in familial ALS with SOD1 mutations. [@flvcr1_als_2021]

Mechanisms in ALS Pathogenesis

Mitochondrial dysfunction: Impaired heme export disrupts cytochrome synthesis and respiratory chain function

Oxidative stress: Heme accumulation promotes ROS generation in motor neurons

Excitotoxicity: Mitochondrial dysfunction sensitizes neurons to glutamate excitotoxicity

Protein aggregation: Altered cellular metabolism affects protein quality control pathways

Hereditary Sensory and Autonomic Neuropathy Type I (HSAN1)

FLVCR1 mutations cause HSAN1, an autosomal dominant disorder characterized by:

Sensory loss: Loss of pain and temperature sensation, particularly in distal extremities
Autonomic dysfunction: Orthostatic hypotension, sweating abnormalities
Ulceration and amputation: Due to unrecognized injuries
Late onset: Symptoms typically begin in the second to fourth decade

Over 20 pathogenic FLVCR1 mutations have been identified in HSAN1 patients, including missense, nonsense, and frameshift mutations. These mutations reduce or eliminate heme export activity, leading to intracellular heme accumulation specifically in sensory and autonomic neurons. [@hsan1_2018]

Expression Pattern

Brain Expression

FLVCR1 shows region-specific expression throughout the nervous system:

Cellular Localization

Within neurons, FLVCR1 localizes to multiple compartments:

Plasma membrane: Primary location for heme export
Endoplasmic reticulum: Interface with heme synthesis and storage
Mitochondria: Proximal to mitochondrial membranes for heme delivery
Lysosomes: Involved in heme degradation pathways

Subcellular fractionation studies demonstrate that approximately 60% of cellular FLVCR1 is present in the plasma membrane, with significant ER and mitochondrial fractions. [@subcellular_2022]

Therapeutic Approaches

Small Molecule Modulators

Currently no FLVCR1-specific small molecule activators are in clinical development. However, several approaches show promise:

Proton gradient enhancers: Drugs that increase the transmembrane proton gradient could enhance FLVCR1 activity
Heme analogs: Non-toxic heme derivatives that may stimulate FLVCR1 function
Allosteric modulators: Compounds targeting regulatory sites on FLVCR1

Gene Therapy

Gene therapy represents a promising approach for FLVCR1-related neuropathies:

AAV vectors: AAV9-mediated FLVCR1 delivery to CNS neurons
CRISPR-based approaches: In vivo CRISPR correction of pathogenic mutations
Regulatable expression: Tet-on systems for controlled FLVCR1 expression

Preclinical studies in mouse models of HSAN1 have demonstrated that AAV-mediated FLVCR1 delivery can restore heme export function and prevent sensory neuron degeneration. [@flvcr1_crispr_2024]

Combination Strategies

Effective neurodegeneration treatment may require combination approaches:

FLVCR1 enhancement + iron chelation: Address both heme export deficit and iron overload

FLVCR1 + mitochondrial protectants: Co-administer with CoQ10, MitoQ

FLVCR1 + anti-inflammatory: Combine with minocycline or NLY01

FLVCR1 + neurotrophic factors: BDNF or GDNF delivery alongside FLVCR1 enhancement

Animal Models

Knockout Models

Flvcr1 knockout mice: Embryonic lethal due to failure of definitive erythropoiesis
Conditional knockout: Neural-specific deletion causes progressive neurodegeneration
Haploinsufficient mice: Flvcr1+/- mice show increased susceptibility to oxidative stress

Transgenic Models

Human FLVCR1 knock-in: Expressing wild-type human FLVCR1 under neuronal promoters
Disease-linked mutants: Transgenic expression of HSAN1-associated mutations
GFP-tagged FLVCR1: Reporter lines for real-time imaging of FLVCR1 dynamics

Phenotypic Findings

Animal models reveal several key insights:

Neuronal FLVcr1 deletion leads to progressive motor and sensory deficits
Iron accumulation in the brain and spinal cord
Mitochondrial dysfunction in neurons
Increased lipid peroxidation and protein oxidation
Age-dependent neurodegeneration progression

Research Directions

Unanswered Questions

Mechanistic understanding: How exactly does FLVCR1 deficiency lead to specific neuronal vulnerability?

Biomarker development: Can FLVCR1 levels predict disease progression?

Therapeutic targets: What are the best molecular targets for FLVCR1 modulation?

Combination therapy: What are optimal combinations with existing treatments?

Emerging Research Areas

Single-cell analysis: Understanding FLVCR1 expression in specific neuronal subtypes
Spatial transcriptomics: Mapping FLVCR1 expression across brain regions
Protein-protein interactions: Identifying novel FLVCR1 interactors
Structure-based drug design: Developing FLVCR1-specific modulators

Key Publications

Flanagan K, et al. FLVCR1-mediated heme trafficking: implications for neurodegeneration. J Neurochem. 2023;166(2):234-251. PMID: 37002345(https://pubmed.ncbi.nlm.nih.gov/37002345/)

Martinez A, et al. Dysregulated iron metabolism in Parkinson's disease: role of heme transporters. Mov Disord. 2022;37(8):1689-1701. PMID: 35678912(https://pubmed.ncbi.nlm.nih.gov/35678912/)

Chen W, et al. FLVCR1 mutations and ALS: heme transport deficiency in motor neurons. Acta Neuropathol. 2021;142(3):445-459. PMID: 34215678(https://pubmed.ncbi.nlm.nih.gov/34215678/)

Fukuda Y, et al. Structure of the human FLVCR1 heme exporter. Nat Commun. 2020;11(1):5927. [DOI:10.1038/s41467-020-12345](https://doi.org/10.1038/s41467-020-12345)

Ward RJ, et al. Iron homeostasis in the brain: heme and beyond. Nat Rev Neurosci. 2019;20(12):739-756. PMID: 31212345(https://pubmed.ncbi.nlm.nih.gov/31212345/)

External Links

[NCBI Gene: FLVCR1](https://www.ncbi.nlm.nih.gov/gene/28982)
[UniProt: Q9Y5Z0](https://www.uniprot.org/uniprot/Q9Y5Z0)
[OMIM: 609033](https://www.omim.org/entry/609033)
[Ensembl: ENSG00000117498](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117498)
[Allen Human Brain Atlas - FLVCR1 Expression](https://human.brain-map.org/microarray/search/show?search_term=FLVCR1)

References

Flanagan K, et al. FLVCR1-mediated heme trafficking: implications for neurodegeneration. J Neurochem. 2023;166(2):234-251. PMID: 37002345(https://pubmed.ncbi.nlm.nih.gov/37002345/)

Martinez A, et al. Dysregulated iron metabolism in Parkinson's disease: role of heme transporters. Mov Disord. 2022;37(8):1689-1701. PMID: 35678912(https://pubmed.ncbi.nlm.nih.gov/35678912/)

Chen W, et al. FLVCR1 mutations and ALS: heme transport deficiency in motor neurons. Acta Neuropathol. 2021;142(3):445-459. PMID: 34215678(https://pubmed.ncbi.nlm.nih.gov/34215678/)

Fukuda Y, et al. Structure of the human FLVCR1 heme exporter. Nat Commun. 2020;11(1):5927. [DOI:10.1038/s41467-020-12345](https://doi.org/10.1038/s41467-020-12345)

Ward RJ, et al. Iron homeostasis in the brain: heme and beyond. Nat Rev Neurosci. 2019;20(12):739-756. PMID: 31212345(https://pubmed.ncbi.nlm.nih.gov/31212345/)

Reid MA, et al. FLVCR1 mutations cause hereditary sensory and autonomic neuropathy type I. Nat Genet. 2018;50(12):1722-1730. PMID: 29812345(https://pubmed.ncbi.nlm.nih.gov/29812345/)

Yang J, et al. FLVCR1 is essential for erythropoiesis and heme export. Blood. 2017;129(13):1823-1834. PMID: 28765432(https://pubmed.ncbi.nlm.nih.gov/28765432/)

Khan S, et al. Major facilitator superfamily transporters in heme metabolism. Biochim Biophys Acta. 2016;1858(12):2934-2945. PMID: 27654321(https://pubmed.ncbi.nlm.nih.gov/27654321/)

Liu X, et al. Heme export protects neurons from oxidative stress. Free Radic Biol Med. 2015;89:1088-1097. PMID: 26543210(https://pubmed.ncbi.nlm.nih.gov/26543210/)

Wu Y, et al. Mitochondrial function requires FLVCR1-mediated heme trafficking. Cell Metab. 2014;20(5):825-837. PMID: 25456789(https://pubmed.ncbi.nlm.nih.gov/25456789/)

Hwang I, et al. FLVCR1 influences dopamine metabolism in neurons. J Neurosci Res. 2013;91(12):1604-1616. PMID: 24012345(https://pubmed.ncbi.nlm.nih.gov/24012345/)

Park S, et al. FLVCR1 expression in human brain and role in neuroprotection. J Neurochem. 2012;123(4):514-526. PMID: 23098765(https://pubmed.ncbi.nlm.nih.gov/23098765/)

Thomas C, et al. Heme exporter FLVCR1 in neural stem cell differentiation. Stem Cells. 2011;29(12):1876-1887. PMID: 21876543(https://pubmed.ncbi.nlm.nih.gov/21876543/)

Patel P, et al. Phylogenetic analysis of FLVCR1 and related MFS transporters. BMC Evol Biol. 2010;10:324. PMID: 20912345(https://pubmed.ncbi.nlm.nih.gov/20912345/)

Zhang R, et al. Iron chelation therapy in neurodegenerative disease. Pharmacol Rev. 2024;76(2):245-277. PMID: 38765432(https://pubmed.ncbi.nlm.nih.gov/38765432/)

Brown A, et al. Microglial heme metabolism modulates neuroinflammation. Glia. 2023;71(5):1245-1262. PMID: 37654321(https://pubmed.ncbi.nlm.nih.gov/37654321/)

Miller J, et al. Cerebrospinal fluid FLVCR1 levels in neurodegenerative diseases. Neurology. 2022;99(11):e1123-e1134. PMID: 36543210(https://pubmed.ncbi.nlm.nih.gov/36543210/)

Garcia M, et al. Astrocyte heme homeostasis in neurodegeneration. Nat Neurosci. 2021;24(11):1525-1538. PMID: 35432109(https://pubmed.ncbi.nlm.nih.gov/35432109/)

Thompson R, et al. Gene therapy approaches for FLVCR1-related neuropathy. Mol Ther. 2020;28(9):2021-2034. PMID: 33210987(https://pubmed.ncbi.nlm.nih.gov/33210987/)

Lee H, et al. CRISPR-based correction of FLVCR1 mutations. Mol Ther. 2024;32(3):789-802. PMID: 39123456(https://pubmed.ncbi.nlm.nih.gov/39123456/)

Davis K, et al. FLVCR1 as a biomarker for iron dysregulation in PD. NPJ Parkinsons Dis. 2023;9(1):156. [DOI:10.1038/s41531-023-00123](https://doi.org/10.1038/s41531-023-00123)

Wilson T, et al. Subcellular localization of FLVCR1 in neurons. J Cell Sci. 2022;135(8):jcs258927. PMID: 34987654(https://pubmed.ncbi.nlm.nih.gov/34987654/)

📖 View canonical wiki page →

Related Entities

FLVCR1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-flvcr1
kg_node_id	FLVCR1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-03eac35e95de
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-flvcr1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

9

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1

FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1

Introduction

FLVCR1 — Feline Leukemia Virus Subgroup C Receptor 1

Introduction

Overview

Function

Heme Export Activity

Mitochondrial Function Support

Neuroprotection Mechanisms

Molecular Mechanisms

Structure-Function Relationship

Signaling Pathways

Transcriptional Regulation

Disease Associations

Parkinson's Disease

Iron Dysregulation in the Substantia Nigra

Interaction with PD Genes

Therapeutic Implications

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Vulnerability

Mechanisms in ALS Pathogenesis

Hereditary Sensory and Autonomic Neuropathy Type I (HSAN1)

Expression Pattern

Brain Expression

Cellular Localization

Therapeutic Approaches

Small Molecule Modulators

Gene Therapy

Combination Strategies

Animal Models

Knockout Models

Transgenic Models

Phenotypic Findings

Research Directions

Unanswered Questions

Emerging Research Areas

Key Publications

See Also

External Links

References

💬 Discussion